Pyrilutamide, also known as KX-826, is an androgen receptor inhibitor being developed by Kintor Pharmaceuticals. It is currently in Phase II clinical trials for androgenetic alopecia (AGA) in China and the US.
The company’s clinical pipeline also includes GT90001, a tyrosine kinase inhibitor targeting ALK-1, Destorsertib, and other disease areas. For more information, buy GlobalData’s drug-specific PTSR and LoA report for Pyrilutamide here.
What is Pyrilutamide?
Pyrilutamide is an androgen receptor (AR) antagonist under development by Kintor Pharmaceuticals. It is currently in phase 2 trials for androgenetic alopecia in both the US and China.
The phase 2 trial in the US will be a randomized placebo-controlled vehicle-controlled study to observe changes in non-vellus target area hair count over 6 months. Enrolment for this trial was expected to be completed last month.
Kintor also announced that Buy pyrilutamide Europe phase 2 clinical trial in China has already been successfully completed. According to Kintor, the results from this trial are likely to be published by the end of this year.
Kintor Pharmaceuticals is a biotechnology company that develops and commercializes small molecule therapeutics for androgen receptor-related diseases. Their drug candidates include proxalutamide (GT0918), KX-826, Destorsertib, and GT20029. Pyrilutamide is a topical solution of 0.5% in an ethanol and propylene glycol vehicle. The raw material pyrilutamide (KX-826) used for this product is tested and confirmed to be >99% pure by a 3rd party laboratory.
Where can I buy Pyrilutamide in Europe?
Pyrilutamide is a drug in development by Kintor Pharmaceuticals for the treatment of androgenic alopecia in males. It is currently undergoing phase II clinical trials in the US and China. Kintor has reported that the first phase II trial of Pyrilutamide met all efficacy and safety endpoints. GlobalData’s drug development report gives insight into the PTSR and LoA of drugs across various stages using drug-specific indication benchmarks built off of 18 years of historical data.
How much does Pyrilutamide cost in Europe?
Buy pyrilutamide in Europe (developmental code name KX-826) is a topical 5-alpha reductase inhibitor, and a high-affinity silent antagonist of the androgen receptor. It is being developed by Kintor Pharmaceutical as a potential treatment for androgenetic alopecia. The drug is being evaluated in phase II clinical trials in the US and China. A large-scale phase III trial is planned for 2022 and should provide more insight into the effectiveness of the drug.
GlobalData’s Pyrilutamide LoA Report includes a comprehensive analysis of the drug’s development history, clinical trial results, and market potential. The report provides indication benchmark PTSR and LoA estimates, built using proprietary data and analytics. The report also features a comprehensive listing of global preclinical and clinical development programs related to the drug. To learn more, download the report now.
Does Pyrilutamide work in Europe?
Pyrilutamide works by blocking DHT and testosterone from binding to androgen receptors in the hair follicle. It is currently being developed by Kintor Pharmaceuticals for androgenic alopecia. A phase 2 trial in the US is expected to begin next year (2021). Kintor also manufactures a topical formulation of pyrilutamide called PyriPure. It is >99% pure and is delivered in a propylene glycol and ethanol vehicle.
The results from pyrilutamide’s phase 2 trials will be important for those seeking alternatives to finasteride. In a press release today, Kintor stated that pyrilutamide’s phase II trials in male patients with androgenetic alopecia in the United States and China met their primary and secondary efficacy endpoints. GlobalData has developed a proprietary drug development process to generate indication benchmark PTSR and LoA scores (likelihood of approval score) for drugs in phase II for Androgenic Alopecia. These PTSR and LoA scores are available for purchase in our Pyrilutamide LoA Report. Buy the report now!